AML

Rajneesh Nath provides an expert's take on the evolution of risk stratification, molecular testing, and treatment of acute myeloid leukemia.

The phase 1b KOMET-001 has been suspended while the developer of KO-539 and FDA investigate a serious safety event.

In the phase 3 QuANTUM-First trial, the combination of quizartinib and chemotherapy met its primary end point and analyses of the secondary end points are ongoing.

Sergio A. Giralt, MD, discusses the key goals of the SIERRA trial which evaluated the safety and efficacy of I apamistamab versus conventional chemotherapy for the treatment of older patients with relapsed/refractory acute myeloid leukemia.

Alice S. Mims, MD, Acute Leukemia Clinical Research director and associate professor in the Division of Hematology at Ohio State University Comprehensive Cancer Center, discusses key updates to the National Comprehensive Cancer Network guidelines on newly-diagnosed acute myeloid leukemia.

Adding the oral mutant isocitrate dehydrogenase-2 inhibitor enasidenib to azacitidine helps to extend ORR in patients with AML, compared to azacitidine monotherapy.

Despite the success of implementing maintenance therapy in other leukemias, the key challenge with administering maintenance therapy in acute myeloid leukemia has been identifying an effective drug.

In an interview with Targeted Oncology, Alice S. Mims, MD, discussed targeting biomarkers in acute myeloid leukemia, and upfront disease management.

Alice S. Mims, MD a hematologist at The Ohio State University Comprehensive Cancer Center, discusses testing and actionable mutations in newly diagnosed acute myeloid leukemia.

The combination of fludarabine, cytarabine, idarubicin and G-CSF and venetoclax produces durable responses and has an acceptable safety profile in patients with newly diagnosed acute myeloid leukemia.

Gwen Nichols, MD, reviews the evolving landscape of acute myeloid leukemia for Leukemia Awareness Month.

Cancer research sites across the United States are evaluating the use of TTI-622 plus azacitidine in patients with T53-mutated acute myeloid leukemia.

In an interview with Targeted Oncology™, Rajneesh Nath, MD, discussed the need for novel treatment for elderly patients with relapsed/refractory AML and how the SIERRA trial is designed to help.

Treatment with ivosidenib tablets in combination with azacitidine led to improvement in event-free survival in patients with previously untreated IDH1-mutated acute myeloid leukemia, meeting the primary end point of the phase 3 AGILE study.

Marcin Kortylewski, PhD, discusses the need for additional strategies for the treatment of acute myeloid leukemia.

Eprenetapop combined with azacitidine has shown positive efficacy as post-transplant maintenance therapy for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia treated in a phase 2 study.

The FDA has lifted its partial clinical hold on a phase 1B study of RVU120, which is an investigation of the agent for the treatment of patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Patients with relapsed/refractory acute myeloid leukemia will now be assesses with the off-the-shelf cell therapy CYNK-001 after a case of conversion to minimal residual disease negativity at its highest dose level.

A small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia showed efficacy and safety with anti-C-type lectin-like molecule-based chimeric antigen receptor T cells.

Rajneesh Nath, MD, discusses outcomes for older patients with acute myeloid leukemia.

Deeper remissions in patients with newly diagnosed, high-risk/secondary acute myeloid leukemia may be achieved with CPX-351 treatment and lead to improvement in overall survival, according to post hoc analyses of a phase 3 study.

In an interview with Targeted Oncology, Sergio A. Giralt, MD, discussed recent data from the study. 

Jorge E. Cortes, MD, discusses the 5-year overall survival results of CPX-351 versus 7+3 in patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

In the phase 1/2 AUGMENT-101 clinical trial, treatment with the novel menin-MLL small molecule inhibitor SNDX-5613 led to robust clinical responses in patients with mixed lineage leukemia rearranged and NPM1c-mutant relapsed or refractory acute leukemias.

The FDA has granted an orphan drug designation to CA-4948, a first-in-class, small-molecule inhibitor of IRAK4, for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.